@FierceBiotech: Brain swelling reported in Lilly Alzheimer's trial. Story | Follow @FierceBiotech
@JohnCFierce: I've been hearing a lot from public biotechs about underpriced shares, to me it sounds that investors want product data/not R&D promises. Follow @JohnCFierce
> If Sanofi-Aventis manages to persuade Genzyme to sell, at least the takeover will get the go-ahead from competition regulators in Europe. Article
> Orexo, a company that develop products based on its reformulation technologies, targeted at the Specialty Pharmaceutical market, has named Anders Lundstrom as the new CEO of the company to lead its commercial development. Story
> Vivus' experimental impotence drug Avanafil helped 80 percent of men achieve erections and two-thirds to have intercourse, Chief Executive Officer Leland Wilson said. As for the company's weight-loss drug Qnexa, Vivus will meet with U.S. regulators to discuss an application later this month and may gain approval to market it by August, Wilson said in an interview today at the J.P. Morgan Healthcare Conference. News
> Dutch biotech Fornix BioSciences said on Thursday it will sell its medical supplies unit Laprolan to Rochester Medical for €10.35 million ($13.5 million), largely completing the company's unwinding. Report
> Patients with high blood pressure treated with a combination of a Novartis hypertension drug and a generic medicine do better than if they take only one of the drugs alone, trial data released on Thursday showed. Item
> A judge accepted a Boston Scientific unit's guilty plea to charges it hid defects in heart defibrillators and placed the company on three years' probation to deter similar conduct. Story
And Finally... Researchers from Rice University and Baylor College of Medicine (BCM) have broken one of the major roadblocks on the path to growing transplantable tissue in the lab: They've found a way to grow the blood vessels and capillaries needed to keep tissues alive. Rice/Baylor release